mirna治疗2型糖尿病的潜力:综述

IF 3.2 Q2 GENETICS & HEREDITY
Epigenetics Insights Pub Date : 2022-10-15 eCollection Date: 2022-01-01 DOI:10.1177/25168657221130041
Pads Palihaderu, Bilm Mendis, Jmkjk Premarathne, Wkrr Dias, Swee Keong Yeap, Wan Yong Ho, A S Dissanayake, I H Rajapakse, P Karunanayake, U Senarath, D A Satharasinghe
{"title":"mirna治疗2型糖尿病的潜力:综述","authors":"Pads Palihaderu,&nbsp;Bilm Mendis,&nbsp;Jmkjk Premarathne,&nbsp;Wkrr Dias,&nbsp;Swee Keong Yeap,&nbsp;Wan Yong Ho,&nbsp;A S Dissanayake,&nbsp;I H Rajapakse,&nbsp;P Karunanayake,&nbsp;U Senarath,&nbsp;D A Satharasinghe","doi":"10.1177/25168657221130041","DOIUrl":null,"url":null,"abstract":"<p><p>MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.</p>","PeriodicalId":41996,"journal":{"name":"Epigenetics Insights","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/2f/10.1177_25168657221130041.PMC9575458.pdf","citationCount":"6","resultStr":"{\"title\":\"Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.\",\"authors\":\"Pads Palihaderu,&nbsp;Bilm Mendis,&nbsp;Jmkjk Premarathne,&nbsp;Wkrr Dias,&nbsp;Swee Keong Yeap,&nbsp;Wan Yong Ho,&nbsp;A S Dissanayake,&nbsp;I H Rajapakse,&nbsp;P Karunanayake,&nbsp;U Senarath,&nbsp;D A Satharasinghe\",\"doi\":\"10.1177/25168657221130041\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.</p>\",\"PeriodicalId\":41996,\"journal\":{\"name\":\"Epigenetics Insights\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2022-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/2f/10.1177_25168657221130041.PMC9575458.pdf\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epigenetics Insights\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25168657221130041\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenetics Insights","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25168657221130041","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 6

摘要

MicroRNA(miRNA)已被确定为一类新兴的治疗干预措施,主要是因为它们在人类和动物体内的细胞外稳定存在,以及它们水平传播和作用的潜力。然而,使用这种技术治疗2型糖尿病还处于初级阶段。mirna在2型糖尿病的发病机制中发挥着重要作用,为利用基于mirna的治疗干预手段治疗该疾病奠定了基础。最近,体内给药miRNA模拟物或抗miRNA导致糖脂代谢的正向调节。此外,一些基于细胞培养的干预措施表明mirna具有β细胞再生潜力。然而,这种基于mirna的治疗方法很少进入临床阶段。因此,未来的研究将确定miRNA治疗T2DM的可能性。本文简要报道了基于mirna治疗2型糖尿病的最新进展、相关意义、差距和对未来研究的建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

Therapeutic Potential of miRNAs for Type 2 Diabetes Mellitus: An Overview.

MicroRNA(miRNA)s have been identified as an emerging class for therapeutic interventions mainly due to their extracellularly stable presence in humans and animals and their potential for horizontal transmission and action. However, treating Type 2 diabetes mellitus using this technology has yet been in a nascent state. MiRNAs play a significant role in the pathogenesis of Type 2 diabetes mellitus establishing the potential for utilizing miRNA-based therapeutic interventions to treat the disease. Recently, the administration of miRNA mimics or antimiRs in-vivo has resulted in positive modulation of glucose and lipid metabolism. Further, several cell culture-based interventions have suggested beta cell regeneration potential in miRNAs. Nevertheless, few such miRNA-based therapeutic approaches have reached the clinical phase. Therefore, future research contributions would identify the possibility of miRNA therapeutics for tackling T2DM. This article briefly reported recent developments on miRNA-based therapeutics for treating Type 2 Diabetes mellitus, associated implications, gaps, and recommendations for future studies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Epigenetics Insights
Epigenetics Insights GENETICS & HEREDITY-
CiteScore
5.10
自引率
0.00%
发文量
10
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信